



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Michael KARAS

Serial No.: 10/790,768

Filed: March 3, 2004

)  
)  
)  
)  
)  
)

Group Art No. 1294

Examiner: TBA

Docket No: 002877.00028

For: INTRACELLULAR DELIVERY OF SMALL MOLECULES, PROTEINS, AND NUCLEIC ACIDS

INFORMATION DISCLOSURE STATEMENTCommissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56 and in compliance with 37 C.F.R. §1.97, Applicant submits herewith Form PTO/SB/08, identifying information for consideration by the Examiner. A copy of the items of information is enclosed.

Applicant does not waive any rights to take appropriate action to establish patentability over the listed documents should they be applied as a reference against the claims of the present application.


Consideration of the cited information and making the same of record in the prosecution of the above-noted application are respectfully requested. Should the Patent and Trademark Office determine that a fee is required, please charge our Deposit Account No. 19-0733.

Respectfully submitted,

BANNER &amp; WITCOFF, LTD.

By:

Joseph M. Skerpon  
Reg. No. 29,864Dated: June 3, 20041001 G Street, N.W.  
Washington, D.C. 20001-4597  
(202) 824-3000



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

Application Number	10/790,768
Filing Date	March 3, 2004
First Named Inventor	Michael Karas
Art Unit	1294
Examiner Name	TBA
Attorney Docket Number	002877.00028

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US- 5,652,122	07-29-1997	Frankel et al.	
		US- 5,670,617	09-23-1997	Frankel et al.	
		US- 5,674,980	10-07-1997	Frankel et al.	
		US- 5,747,641	05-05-1998	Frankel et al.	
		US- 5,804,604	09-08-1998	Frankel et al.	
		US- 5,807,746	09-15-1998	Lin et al.	
		US- 6,093,809	07-25-2000	Cech et al.	
		US- 6,166,178	12-26-2000	Cech et al.	
		US- 6,261,836	07-17-2001	Cech et al.	
		US- 6,306,993	10-23-2001	Rothbard et al.	
		US- 6,358,739	03-19-2002	Baetge et al.	
		US- 2002-0009491 A1	01-24-2002	Rothbard et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		EP - 0 841 396 A1	05-13-1996	Cech et al.		*
		WO - 99/50386	10-07-1999	Morin		*
		WO - 00/34308	06-15-2000	Dowdy et al.		*
		WO - 00/61617	10-19-2000	Baetge et al.		*
		WO - 00/62067	10-19-2000	Dowdy		*
		WO - 01/15511	03-08-2001	Robbins et al.		*

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<i>Application Number</i>	10/790,768
		<i>Filing Date</i>	March 3, 2004
		<i>First Named Inventor</i>	Michael Karas
		<i>Art Unit</i>	1294
		<i>Examiner Name</i>	TBA
(Use as many sheets as necessary)		<i>Attorney Docket Number</i>	002877.00028
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		WENDER, et al., "The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters" PNAS, vol. 97, no. 24, November 21, 2000, pp. 13003-13008.	*
		WALTHER, et al., "Expression of Granulosa Cell-Specific Genes and Induction of Apoptosis in Conditionally Immortalized Granulosa Cell Lines Established from H-2K <sup>b</sup> -tsA58 Transgenic Mice" Biology of Reproduction, vol. 60, 1999, pp. 1078-1086.	*
		HO, et al., "Synthetic Protein Transduction Domains: Enhanced Transduction Potential <i>in Vitro</i> and <i>in Vivo</i> " Cancer Research, vol. 61, January 15, 2001, pp. 474-477.	*
		ASOH, et al., "Protection against ischemic brain injury by protein therapeutics" PNAS, vol. 99, no. 26, December 24, 2002, pp. 17107-17112.	*
		CAO, et al., "In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis" Journal of Neuroscience, vol. 22, no. 13, July 1, 2002, pp. 5423-5431.	*
		Pierce Chemical Technical Library, "Cross - Linking: Homobifunctional Cross-linkers" <a href="http://www.piercenet.com">http://www.piercenet.com</a>	*
		Pierce Chemical Technical Library, "Cross - Linking: Heterobifunctional Cross-linkers" <a href="http://www.piercenet.com">http://www.piercenet.com</a>	*
		Pierce Chemical Technical Library, "Cross - Linking: Applications for Use of Cross-linkers" <a href="http://www.piercenet.com">http://www.piercenet.com</a>	*
		Pierce Chemical Technical Library, "Cross - Linking: Glossary of Cross-linking Terms" <a href="http://www.piercenet.com">http://www.piercenet.com</a>	*

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.